Saudi Arabia: Discover How King Faisal Specialist Hospital Leads In CAR-T Cell Therapy And CRISPR Innovations

King Faisal Specialist Hospital & Research Centre (KFSHRC) stands as a beacon of healthcare innovation, pushing the boundaries of medical science through its adoption of revolutionary treatments such as CAR-T cell therapy and the use of CRISPR gene editing. This institution not only offers new hope to patients through these advanced therapies but also significantly improves healthcare outcomes across the region.

For more than half a century, KFSHRC has led the charge in cancer treatment, showcasing its expertise through the Cancer Center of Excellence. In the year 2023 alone, it has addressed 25% of all cancer cases in the nation, with remarkable success rates: half of these patients achieved full recovery, and for those battling leukaemia, the recovery rate soared to an impressive 90%. The hospital's commitment to pioneering care is evident in its successful administration of over 100 CAR-T cell therapy treatments. This innovative approach, which re-engineers a patient's immune cells to fight cancer, has been instrumental in KFSHRC's achievement of a 97% five-year survival rate for children facing renal tumors.

The introduction of CAR-T cell therapy at KFSHRC marked a significant milestone in 2021 when a 13-year-old leukemia patient received this cutting-edge treatment. This, along with KFSHRC’s esteemed bone marrow transplant program, underscores the hospital’s preeminence in advanced cancer treatment. Such innovations not only reinforce KFSHRC's position as a leader in the medical field but also highlight its role as one of the select global centers authorized to offer CAR-T therapy.

KFSHRC is also making strides in genomic medicine, notably through the development of the country's first genetically engineered mice using CRISPR-Cas9 gene-editing technology. This advancement is part of the broader Saudi Human Genome Program aimed at tailoring treatments to individual genetic profiles, thus pioneering the next wave of personalized medicine. The hospital's groundbreaking work in immunology further exemplifies its leading role in healthcare innovation, with successful gene therapy trials for haemophilia A and Paroxysmal Nocturnal Haemoglobinuria (PNH) significantly enhancing patient lives while reducing the financial burden of treatments.

Moreover, KFSHRC's innovative spirit extends beyond our planet. The hospital recently conducted experiments on the International Space Station (ISS) to explore immune cell behavior and RNA modifications in the space environment. These studies could lead to novel therapeutic strategies for managing diseases in conditions of microgravity and beyond, showcasing KFSHRC's commitment to advancing medical science in even the most unique settings.

KFSHRC has been recognized as the top medical institution in the Middle East and Africa and ranks 20th worldwide among the top 250 Academic Medical Centers for two consecutive years. Additionally, it has been acknowledged as the most valuable healthcare brand in the MENA region according to the 2024 Brand Finance rankings and earned a spot among Newsweek magazine's best 250 hospitals globally.